Immune System Key Ltd.
Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.
LATEST NEWS
Phase II update – A second patient (92 years old) had a strong reduction in blasts in the bone marrow
No side effects were recorded
Update from AML human trial in Miami
Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:
8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.
In cohort 1 (dose=6mg/m^2) three patients were enrolled.
The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third patient was using a wheelchair when enrolled to the trial. This patient is now alive for 12 months, walking free and with stable disease.
In cohort 2 (dose=96mg/m^2) two patients were enrolled.
The first patient was using a wheelchair when enrolled to the trial. This patient is now 10 months into the trial doing gymnastics and feels great.
The cancer cells in her bone marrow and blood
Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors
The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.
PHASE 1B/2A Clinical trial started
The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.
Cooperation with Harvard Medical School (MGH)
ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
